Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat.
Tetraphase`s proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates.
Tetraphase common stock trades under the NASDAQ symbol `TTPH.` Tetraphase is well positioned to be a major player in the multidrug-resistant arena.
-
Number of Employees:
25-100
-
Annual Revenue:
$10-50 Million